113 related articles for article (PubMed ID: 9877309)
1. Pharmacokinetic differences between lansoprazole enantiomers in rats.
Arimori K; Yasuda K; Katsuki H; Nakano M
J Pharm Pharmacol; 1998 Nov; 50(11):1241-5. PubMed ID: 9877309
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Masa K; Hamada A; Arimori K; Fujii J; Nakano M
Biol Pharm Bull; 2001 Mar; 24(3):274-7. PubMed ID: 11256484
[TBL] [Abstract][Full Text] [Related]
4. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans.
Katsuki H; Yagi H; Arimori K; Nakamura C; Nakano M; Katafuchi S; Fujioka Y; Fujiyama S
Pharm Res; 1996 Apr; 13(4):611-5. PubMed ID: 8710755
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic differences between pantoprazole enantiomers in rats.
Xie Z; Zhang Y; Xu H; Zhong D
Pharm Res; 2005 Oct; 22(10):1678-84. PubMed ID: 16180125
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes.
Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(1):127-33. PubMed ID: 11419737
[TBL] [Abstract][Full Text] [Related]
8. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
Masa K; Arimori K; Nakayama T; Miyamoto S; Fujii J; Nakano M
Biol Pharm Bull; 1999 May; 22(5):504-9. PubMed ID: 10375172
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction.
Miura M; Tada H; Suzuki T
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 May; 804(2):389-95. PubMed ID: 15081934
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
11. Identification of the human P450 enzymes involved in lansoprazole metabolism.
Pearce RE; Rodrigues AD; Goldstein JA; Parkinson A
J Pharmacol Exp Ther; 1996 May; 277(2):805-16. PubMed ID: 8627562
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.
Kim KA; Kim MJ; Park JY; Shon JH; Yoon YR; Lee SS; Liu KH; Chun JH; Hyun MH; Shin JG
Drug Metab Dispos; 2003 Oct; 31(10):1227-34. PubMed ID: 12975331
[TBL] [Abstract][Full Text] [Related]
13. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Uno T; Yasui-Furukori N; Takahata T; Sugawara K; Tateishi T
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):309-14. PubMed ID: 15664363
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of lansoprazole.
Landes BD; Petite JP; Flouvat B
Clin Pharmacokinet; 1995 Jun; 28(6):458-70. PubMed ID: 7656504
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.
Cassiano NM; Oliveira RV; Bernasconi GC; Cass QB
Chirality; 2012 Apr; 24(4):289-93. PubMed ID: 22344845
[TBL] [Abstract][Full Text] [Related]
17. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
Miura M; Inoue K; Satoh S; Itoh Y; Kagaya H; Tada H; Tanaka Y; Habuchi T; Suzuki T
Clin Drug Investig; 2007; 27(4):251-8. PubMed ID: 17358097
[TBL] [Abstract][Full Text] [Related]
18. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
20. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
